VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Wednesday, Jul 19, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

There is nothing unexpected in terms of the adverse events seen with nivolumab and cabozantinib, states Apolo. Overall, the regimen has been well tolerated.

Responses have been seen in rare genitourinary tumors, explains Apolo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x